{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:09:41Z","timestamp":1783735781284,"version":"3.55.0"},"reference-count":29,"publisher":"King Faisal Specialist Hospital and Research Centre","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Saudi Med"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.5144\/0256-4947.2019.265","type":"journal-article","created":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T15:51:28Z","timestamp":1565020288000},"page":"265-278","source":"Crossref","is-referenced-by-count":24,"title":["Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia"],"prefix":"10.5144","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5991-5318","authenticated-orcid":true,"given":"Ahmad S.","family":"Hersi","sequence":"first","affiliation":[{"name":"From the Department of Cardiac Science, College of Medicine, King Saud University, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine M.","family":"Osenenko","sequence":"additional","affiliation":[{"name":"From the ICON Epidemiology, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sid Ahmed","family":"Kherraf","sequence":"additional","affiliation":[{"name":"From the Innovative Health, Pfizer, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayman Abdel","family":"Aziz","sequence":"additional","affiliation":[{"name":"From the Global Innovative Pharma, Pfizer, Jeddah, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Joseph","family":"Sambrook","sequence":"additional","affiliation":[{"name":"From the ICON Epidemiology, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3134","reference":[{"issue":"11","key":"e_1_3_3_2_2","doi-asserted-by":"crossref","first-page":"e101","DOI":"10.1016\/j.jacc.2010.09.013","article-title":"2011 ACCF\/AHA\/HRS focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation","volume":"57","author":"Fuster V","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"18","key":"e_1_3_3_3_2","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"285","author":"Go AS","year":"2001","journal-title":"JAMA"},{"issue":"6","key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition)","volume":"133","author":"Singer DE","year":"2008","journal-title":"Chest"},{"issue":"19","key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1093\/eurheartj\/ehq278","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)","volume":"31","author":"Camm A","year":"2010","journal-title":"Eur Heart J"},{"issue":"5","key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/heart.86.5.516","article-title":"Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew\/Paisley study","volume":"86","author":"Stewart S","year":"2001","journal-title":"Heart"},{"issue":"6","key":"e_1_3_3_7_2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1378\/chest.11-2888","article-title":"The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe","volume":"142","author":"Lip G","year":"2012","journal-title":"Chest"},{"issue":"3","key":"e_1_3_3_8_2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/0003319714529180","article-title":"Saudi Atrial Fibrillation Survey: National, Observational, Cross-sectional Survey Evaluating Atrial Fibrillation Management and the Cardiovascular Risk Profile of Patients With Atrial Fibrillation","volume":"66","author":"Hersi A","year":"2015","journal-title":"Angiology"},{"issue":"2","key":"e_1_3_3_9_2","first-page":"17","article-title":"Health care resource utilization and costs in individuals with atrial fibrillation in United Arab Emirates and Kingdom of Saudi Arabia: a retrospective cohort study","volume":"4","author":"Johnston KM","year":"2015","journal-title":"Int J Intern Med"},{"key":"e_1_3_3_10_2","unstructured":"The World Bank: Saudi Arabia data [online]. Available at: http:\/\/data.worldbank.org\/country\/saudi-arabia. [Accessed May 18 2017]"},{"issue":"38","key":"e_1_3_3_11_2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof P","year":"2016","journal-title":"Eur Heart J"},{"issue":"9","key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly SJ","year":"2011","journal-title":"N Engl J Med"},{"issue":"11","key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","journal-title":"N Engl J Med"},{"key":"e_1_3_3_14_2","unstructured":"Clinical practice guideline on antithrombotic treatment of patients with non-valvular atrial fibrillation [online]. The Saudi Center for Evidence Based Health Care 2014. Available at: http:\/\/www.moh.gov.sa\/endepts\/TCP\/Documents\/2.%20Atrial%20Fibrillation%20-%20Antithrombotic%20Treatment%20of%20Patients%20with%20Non-valvular%20Atrial%20Fibrillation.pdf. [Accessed June 10 2017]"},{"issue":"28","key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1093\/eurheartj\/ehu006","article-title":"Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation","volume":"35","author":"Dorian P","year":"2014","journal-title":"Eur Heart J"},{"issue":"2","key":"e_1_3_3_16_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clinthera.2013.12.011","article-title":"Cost-effectiveness of apixaban versus other new oral anticoagulants for stroke prevention in atrial fibrillation","volume":"36","author":"Lip GY","year":"2014","journal-title":"Clin Ther"},{"key":"e_1_3_3_17_2","unstructured":"Human drugs database [online]. Saudi Food & Drug Authority 2014. Available at: https:\/\/www.sfda.gov.sa\/en\/drug\/search\/Pages\/default.aspx (Accessed June 24 2014]"},{"issue":"10","key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"e_1_3_3_19_2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","journal-title":"N Engl J Med"},{"issue":"20","key":"e_1_3_3_20_2","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly SJ","year":"2009","journal-title":"N Engl J Med"},{"key":"e_1_3_3_21_2","volume-title":"Consumer price indices [online]"},{"issue":"6","key":"e_1_3_3_22_2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D scores for the United Kingdom","volume":"31","author":"Sullivan PW","year":"2011","journal-title":"Med Decis Making"},{"key":"e_1_3_3_23_2","volume-title":"Life tables by country - Saudi Arabia (online)"},{"issue":"9","key":"e_1_3_3_24_2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness \u2013 the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann PJ","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"e_1_3_3_25_2","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/00019053-200826090-00004","article-title":"The NICE cost-effectiveness threshold: what it is and what that means","volume":"26","author":"McCabe C","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"e_1_3_3_26_2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse SD","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"433","DOI":"10.5144\/0256-4947.2017.433","article-title":"Cost-effectiveness of oral agents in relapsing-remitting multiple sclerosis compared to interferon-based therapy in Saudi Arabia","volume":"37","author":"Alsaqaaby MF","year":"2017","journal-title":"Ann Saudi Med"},{"issue":"10","key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40261-014-0224-z","article-title":"Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium","volume":"34","author":"Kongnakorn T","year":"2014","journal-title":"Clin Drug Investig"},{"issue":"8","key":"e_1_3_3_29_2","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3111\/13696998.2014.923891","article-title":"Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin","volume":"17","author":"Lanitis T","year":"2014","journal-title":"J Med Econ"},{"issue":"16","key":"e_1_3_3_30_2","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1001\/archinte.1996.00440150083009","article-title":"The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life","volume":"156","author":"Gage BF","year":"1996","journal-title":"Arch Intern Med"}],"container-title":["Annals of Saudi Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T06:59:32Z","timestamp":1573023572000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.annsaudimed.net\/doi\/10.5144\/0256-4947.2019.265"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["10.5144\/0256-4947.2019.265"],"URL":"https:\/\/doi.org\/10.5144\/0256-4947.2019.265","relation":{},"ISSN":["0256-4947","0975-4466"],"issn-type":[{"value":"0256-4947","type":"print"},{"value":"0975-4466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7]]}}}